Results 161 to 170 of about 26,389 (264)

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Clinical and Economic Trade-Offs in Antifungal Therapy for Invasive Aspergillosis and Mucormycosis: A Markov Model-Based Analysis. [PDF]

J Fungi (Basel)
Rico Mendoza A, Porras Ramirez A, Encinales L, Madiedo O, Carrillo Encinales M, Duque Bolivar JP, Ramon Cuellar JF, Urquijo Mendez JA, Moreno Perilla Z, Jurado Zambrano R.   +9 more
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Economic Evaluation of a Digital Psychobehavioral Intervention for Chronic Inflammatory Skin Disease (MindMySkin): Protocol for a Trial-Based Cost-Effectiveness Analysis. [PDF]

JMIR Res Protoc
Choi E, Neo SH, Phan P, Petrou S.
europepmc   +1 more source

Cost-Effectiveness of Endovascular vs Open Surgery for Chronic Limb-Threatening Ischemia.

JAMA Netw Open
Zafari Z, Najafzadeh M, Mahesri M, Shin H, Goodney PP, Conte MS, Creager MA, Dake MD, Kaufman JA, Powell RJ, White CJ, Strong MB, Rosenfield K, Farber A, Menard MT, Choudhry NK.   +15 more
europepmc   +1 more source

Long-Term Cost and Health Impact of a Digital Obesity Intervention in Germany: Economic Modeling Study. [PDF]

JMIR Form Res
Walter E, Kaup M, Althaus AE, Fehring L.
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Manufacturing cost analysis and exploratory economic evaluation of natural killer cell immunotherapy for paediatric solid tumors. [PDF]

Clin Transl Immunology
Wahid ST, Elliott M, Wang Y, Nicholls W, Omer N, Souza-Fonseca-Guimaraes F, Tuffaha H.   +6 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source